Pyruvate-enriched resuscitation for shock

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

This commentary addresses the recent retraction of an article which reported favorable outcomes in septic patients treated with intravenous pyruvate. The retracted report was cited in the authors’ recent minireview on the cellular mechanisms and clinical application of pyruvate to improve cardiac performance. Because the retracted article reports pyruvate-enhanced resuscitation of critically ill patients, the authors wish to inform the readership, especially critical care providers, that this particular clinical application of pyruvate is not now supported by robust evidence. After discussing the retraction’s implications for the clinical application of pyruvate-enriched resuscitation for sepsis, this commentary summarizes the extensive preclinical evidence of the efficacy and mechanisms of pyruvate resuscitation in animal models of hemorrhagic and septic shock, which argues for renewed clinical investigation of pyruvate-enriched resuscitation. Impact statement: This commentary addresses the recent retraction of a clinical report of significant benefits of intravenous pyruvate resuscitation in septic patients, including sharply lowered mortality and decreased circulating pro-inflammatory cytokines, which was cited in the authors’ minireview in Experimental Biology and Medicine. The potential implications of the retraction, and the extensive preclinical evidence supporting the use of pyruvate-enriched resuscitation for shock states, are summarized and discussed.

Original languageEnglish
Pages (from-to)663-664
Number of pages2
JournalExperimental Biology and Medicine
Volume243
Issue number8
DOIs
StatePublished - 1 May 2018

Fingerprint

Resuscitation
Pyruvic Acid
Shock
Hemorrhagic Shock
Bioelectric potentials
Critical Care
Septic Shock
Critical Illness
Medicine
Biomedical Research
Sepsis
Animals
Animal Models
Cytokines

Keywords

  • Hemorrhage
  • inflammation
  • pyruvate
  • sepsis
  • septic shock

Cite this

@article{80f0805011c34f4e9d741b8f8697de89,
title = "Pyruvate-enriched resuscitation for shock",
abstract = "This commentary addresses the recent retraction of an article which reported favorable outcomes in septic patients treated with intravenous pyruvate. The retracted report was cited in the authors’ recent minireview on the cellular mechanisms and clinical application of pyruvate to improve cardiac performance. Because the retracted article reports pyruvate-enhanced resuscitation of critically ill patients, the authors wish to inform the readership, especially critical care providers, that this particular clinical application of pyruvate is not now supported by robust evidence. After discussing the retraction’s implications for the clinical application of pyruvate-enriched resuscitation for sepsis, this commentary summarizes the extensive preclinical evidence of the efficacy and mechanisms of pyruvate resuscitation in animal models of hemorrhagic and septic shock, which argues for renewed clinical investigation of pyruvate-enriched resuscitation. Impact statement: This commentary addresses the recent retraction of a clinical report of significant benefits of intravenous pyruvate resuscitation in septic patients, including sharply lowered mortality and decreased circulating pro-inflammatory cytokines, which was cited in the authors’ minireview in Experimental Biology and Medicine. The potential implications of the retraction, and the extensive preclinical evidence supporting the use of pyruvate-enriched resuscitation for shock states, are summarized and discussed.",
keywords = "Hemorrhage, inflammation, pyruvate, sepsis, septic shock",
author = "Mallet, {Robert T.} and Albert Yurvati and Rolf B{\"u}nger",
year = "2018",
month = "5",
day = "1",
doi = "10.1177/1535370218773717",
language = "English",
volume = "243",
pages = "663--664",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Inc.",
number = "8",

}

Pyruvate-enriched resuscitation for shock. / Mallet, Robert T.; Yurvati, Albert; Bünger, Rolf.

In: Experimental Biology and Medicine, Vol. 243, No. 8, 01.05.2018, p. 663-664.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Pyruvate-enriched resuscitation for shock

AU - Mallet, Robert T.

AU - Yurvati, Albert

AU - Bünger, Rolf

PY - 2018/5/1

Y1 - 2018/5/1

N2 - This commentary addresses the recent retraction of an article which reported favorable outcomes in septic patients treated with intravenous pyruvate. The retracted report was cited in the authors’ recent minireview on the cellular mechanisms and clinical application of pyruvate to improve cardiac performance. Because the retracted article reports pyruvate-enhanced resuscitation of critically ill patients, the authors wish to inform the readership, especially critical care providers, that this particular clinical application of pyruvate is not now supported by robust evidence. After discussing the retraction’s implications for the clinical application of pyruvate-enriched resuscitation for sepsis, this commentary summarizes the extensive preclinical evidence of the efficacy and mechanisms of pyruvate resuscitation in animal models of hemorrhagic and septic shock, which argues for renewed clinical investigation of pyruvate-enriched resuscitation. Impact statement: This commentary addresses the recent retraction of a clinical report of significant benefits of intravenous pyruvate resuscitation in septic patients, including sharply lowered mortality and decreased circulating pro-inflammatory cytokines, which was cited in the authors’ minireview in Experimental Biology and Medicine. The potential implications of the retraction, and the extensive preclinical evidence supporting the use of pyruvate-enriched resuscitation for shock states, are summarized and discussed.

AB - This commentary addresses the recent retraction of an article which reported favorable outcomes in septic patients treated with intravenous pyruvate. The retracted report was cited in the authors’ recent minireview on the cellular mechanisms and clinical application of pyruvate to improve cardiac performance. Because the retracted article reports pyruvate-enhanced resuscitation of critically ill patients, the authors wish to inform the readership, especially critical care providers, that this particular clinical application of pyruvate is not now supported by robust evidence. After discussing the retraction’s implications for the clinical application of pyruvate-enriched resuscitation for sepsis, this commentary summarizes the extensive preclinical evidence of the efficacy and mechanisms of pyruvate resuscitation in animal models of hemorrhagic and septic shock, which argues for renewed clinical investigation of pyruvate-enriched resuscitation. Impact statement: This commentary addresses the recent retraction of a clinical report of significant benefits of intravenous pyruvate resuscitation in septic patients, including sharply lowered mortality and decreased circulating pro-inflammatory cytokines, which was cited in the authors’ minireview in Experimental Biology and Medicine. The potential implications of the retraction, and the extensive preclinical evidence supporting the use of pyruvate-enriched resuscitation for shock states, are summarized and discussed.

KW - Hemorrhage

KW - inflammation

KW - pyruvate

KW - sepsis

KW - septic shock

UR - http://www.scopus.com/inward/record.url?scp=85046993244&partnerID=8YFLogxK

U2 - 10.1177/1535370218773717

DO - 10.1177/1535370218773717

M3 - Comment/debate

C2 - 29763385

AN - SCOPUS:85046993244

VL - 243

SP - 663

EP - 664

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 8

ER -